The first patient has been dosed in a P-II study evaluating IBI112 (anti-IL-23p19 mAb) in 150 patients with mod. to sev. active UC
The primary objective of the study is to evaluate the efficacy, safety, PK & immunogenicity of IBI112 induction and maintenance therapy in patients with active UC. In the P-I study, IBI112 showed favorable safety and tolerability profiles and initially showed promise for a longer dosing interval & more patient-friendly treatment regimen
The therapy offers an effective treatment option for IBD including UC & other autoimmune diseases. In the preclinical study, the therapy demonstrated that it has a clear target and well-elucidated MoA along with a significant anti-inflammatory effect
Ref: PRNewswire | Image: Innovent
